Skip to main content
Premium Trial:

Request an Annual Quote

Synthego Engineered Cells Portfolio

Synthego has launched its Engineered Cells product portfolio, giving customers immediate access to Knockout Clone and Pool, and Advanced Cells. The Knockout Cell Pools provide researchers the ability to purchase engineered cell populations with a first-ever guaranteed knockout frenquency of 50 percent or greater with a single click. These engineered cells will be delivered in as few as four weeks. The high knockout frequency allows researchers to use the pools directly in many assays or efficiently generate clonal populations.

Knockout Cell Clones give researchers the most complete access to CRISPR with no additional steps required. These engineered cell clones are 100 percent sequence verified to contain the gene of interest knocked out and are delivered in as few as eight weeks.

Advanced Cells are optimal for researchers working on more complex gene editing projects, the company said. Researchers can use Synthego's expertise to design, execute, and analyze genome editing projects that go beyond single-gene knockouts, including knock-ins (protein modifications, protein tagging, transgene insertions) and editing complex primary cells and stem cells.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.